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Abstract
Introduction The objective of the present study was to explore
a continuous intravenous furosemide regimen that adapts to
urine output in neonates treated with extracorporeal membrane
oxygenation (ECMO).
Methods Seven neonates admitted to a paediatric surgical
intensive care unit for ECMO therapy were treated with a
furosemide regimen consisting of a loading bolus (1–2 mg/kg)
followed by a continuous infusion at 0.2 mg/kg per hour, which
was adjusted according to the target urine production of 6 ml/
kg per hour. Therapeutic drug monitoring for furosemide
concentrations in blood was performed.
Results The mean ± standard deviation furosemide dose was
0.17 ± 0.06 mg/kg per hour, 0.08 ± 0.04 mg/kg per hour and
0.12 ± 0.07 mg/kg per hour, respectively, on the first day,
second day and third day of the study. The median (range of the
urine production of the study subjects) urine production over the
consecutive study days was 6.8 (0.8–8.4) mg/kg per hour, 6.0
(4.7–8.9) mg/kg per hour and 5.4 (3.4–10.1) ml/kg per hour.
The target urine production was reached after a median time of
7 (3–37) hours. The regimen was haemodynamically well
tolerated and the median furosemide serum concentration was
3.1 (0.4–12.9) μg/ml, well below the toxic level.
Conclusion The evaluated furosemide infusion appears an
effective means to reduce volume overload in neonates treated
with ECMO. The data of this preliminary study suggest that the
starting dose of furosemide was too high, however, because the
urine output was excessive and required frequent adaptations.
The results of this study therefore indicate that a novel
pharmacokinetic/pharmacodynamic model needs to be
developed for neonates treated with ECMO.
Introduction
Extracorporeal membrane oxygenation (ECMO) is used mainly
in neonates to treat a variety of cardiorespiratory problems
such as meconium aspiration syndrome, congenital diaphrag-
matic hernia, persistent pulmonary hypertension of the new-
born, and sepsis/pneumonia [1].
The ECMO circuit, like the cardiopulmonary bypass (CPB) cir-
cuit, triggers an important inflammatory reaction and is clini-
cally associated with the so-called capillary leakage syndrome,
resulting in intravascular hypovolaemia and renal hypoper-
fusion [2]. Consequently, in the initial phase (in the first 24–48
hours) the ECMO patient becomes usually increasingly oede-
matous. Diuretics, especially loop diuretics such as furosem-
ide, are therefore the mainstay in the enhancement of diuresis
to mobilize fluid excess. Furosemide is often used as a contin-
uous infusion in patients treated with ECMO, based upon the
observations in infants after CPB surgery [3-6].
We recently made an inventory of furosemide regimens used
in neonates treated with ECMO and concluded that continu-
ous intravenous furosemide was frequently used, but the used
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regimens varied widely in continuous doses and additional
intermittent doses [7]. Although adequate urine output was
achieved within 24 hours with all regimens, the used furosem-
ide regimens might not be the optimal regimen for neonates
treated with ECMO. In an accompanying editorial it was sug-
gested that development of more standardized and efficacious
dosing regimens would be preferable [8].
Since ECMO and CPB result in fluid overload, at least partially
based on the same pathophysiology, it seems reasonable to
assume that pharmacokinetic/pharmacodynamic (PK/PD)
models developed for infants following cardiac surgery might
also be applicable for neonates treated with ECMO [9]. We
therefore conducted a prospective exploratory study in
neonates treated with ECMO to evaluate a suggested furo-
semide regimen that was initially developed for infants after
CPB surgery. The regimen consisted of a continuous furosem-
ide infusion at a rate of 0.2 mg/kg per hour that was preceded
by a loading bolus. The aim was to achieve a urine output of 6
ml/kg per hour. The main objectives of the study were to estab-
lish the efficacy of such a regimen and also to document
serum furosemide concentrations to rule out ototoxic levels.
In the present article we report the findings of the proposed
furosemide regimen in neonates treated with venoarterial
ECMO in our unit.
Materials and methods
The study was performed at the paediatric surgical intensive
care unit of the Sophia Children's Hospital of Erasmus Medical
Centre in Rotterdam, The Netherlands. The study protocol
was approved by the Committee on Medical Ethics of the
Erasmus Medical Centre and was conducted according to the
principles of the Declaration of Helsinki. Parental written
informed consent was obtained for all patients.
Patients
Consecutive patients younger than 1 year of age who were
admitted to our unit for ECMO treatment were enrolled in the
study. Continuous intravenous furosemide was started when
the patient was in a cardiovascular stable condition. The
patient was considered cardiovascularly stable if there was no
need for ongoing fluid resuscitation and/or for an increase in
inotropic support. The amount of inotropic support was quan-
tified by the vasopressor score [10,11].
Demographic and clinical data were collected from the patient
charts and from the electronic patient data management sys-
tem. This data included the gestational and postpartum age,
gender, weight, diagnosis, the ECMO flow and duration of
ECMO treatment, the time when continuous furosemide infu-
sion was started, the doses and duration of continuous intra-
venous furosemide, additional loop diuretics, inotropic
support, and fluid intake.
The following variables were measured before the study and
at regular time intervals during the study for a maximum of 72
hours: urine output, heart rate, and mean arterial blood pres-
sure. Serum albumin, creatinine, and BUN levels, and the arte-
rial blood gas, were determined at regular intervals during the
observation period.
Blood samples for the determination of serum furosemide con-
centrations were taken 10 minutes after the (loading) bolus
dose, and additional samples were taken when possible. All
patients had a urinary catheter as part of standard treatment
according to the standard hospital ECMO protocol. The
observation period for the study was 72 hours after the start of
the continuous infusion. Serum electrolyte levels were closely
monitored during the continuous intravenous furosemide ther-
apy, and supplements were given if necessary.
Furosemide regimen
The continuous furosemide infusion is started at a rate of 0.2
mg/kg per hour and is preceded by a loading bolus, the dose
of which is dependent on renal function. Patients with normal
renal function received 1 mg/kg and patients with acute renal
failure received 2 mg/kg. Acute renal failure was defined on
plasma creatinine levels and depended on the gestational and
postpartum age [12].
The aim was to reach and maintain a urine output of 6 ml/kg
per hour. Adaptation of the infusion rate was allowed when the
target urine level was not reached at two consecutive hourly
assessments. If the urine production was less than 4 ml/kg per
hour, the rate of infusion could be increased; and if urine pro-
duction was more than 8 ml/kg per hour, the infusion rate
could be decreased.
Sampling and assays
Routine blood samples were analysed at the Clinical Chemis-
try Laboratory of the Erasmus Medical Centre. Furosemide
concentrations were measured using a validated high-per-
formance liquid chromatography method routinely applied at
the laboratory of Clinical Pharmacy and Toxicology of Leiden
University Medical Center [6]. For determination in serum, the
coefficient of variation of the assay at 1 μg/ml was 2%, and the
reproducibility of the slope was 8.9%.
Data analysis
Data showing a skewed distribution are presented as the
median (range), while the normally distributed data are pre-
sented as the mean ± standard deviation. The outcome evalu-
ation included the median urine production over each 24-hour
time interval and the time at which the target urine production
was reached. The time to attain the target urine production
was defined as the time point at which urine production was
at least 6 ml/kg per hour for two consecutive hourly
assessments.Available online http://ccforum.com/content/11/5/R111
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Results
General
Continuous intravenous furosemide was evaluated in seven
patients in whom venoarterial ECMO was performed. The
study population consisted of six female patients and one male
patient. The median gestational age was 40 (26–41) weeks.
On admission, the median postpartum age was 3 (0–136)
days and the median weight was 3.8 (3.0–5.0) kg. ECMO was
performed for meconium aspiration syndrome in three
patients, for respiratory insufficiency in three patients, and for
persistent pulmonary hypertension of the newborn in one
patient. ECMO was started 2 (0–65) hours after admission. All
patients were weaned from ECMO after 109 (47–272) hours
and were discharged from the intensive care unit after 7 (4–
33) days.
Extracorporeal membrane oxygenation regimen
The priming volume of the ECMO circuit was approximately
400 ml, and the solution consisted of albumin and packed red
blood cells. The initial median ECMO flow was 101 (59–132)
ml/kg per minute, equal to 80% of the total cardiac output. The
median ECMO flow at the start of the continuous furosemide
therapy and after 8, 16, 24, 48, and 72 hours of continuous
furosemide infusion were, respectively, 109 (59–139) ml/kg
per minute, 102 (76–139) ml/kg per minute, 97 (67–167) ml/
kg per minute, 125 (76–167) ml/kg per minute, 116 (52–153)
ml/kg per minute, and 82 (40–139) ml/kg per minute.
Furosemide regimen
Continuous furosemide infusion was started 3 (0–22) hours
after the start of ECMO at a rate of 0.2 mg/kg per hour and
was preceded by a loading bolus of 1 ± 0.04 mg/kg. The mean
± standard deviation furosemide dose was 0.17 ± 0.06 mg/kg
per hour, 0.08 ± 0.04 mg/kg per hour, and 0.12 ± 0.07 mg/kg
per hour, respectively, over the first day, second day, and third
day of the study.
The dose needed to be decreased from the first to the second
day in five out of the seven patients, indicating that the starting
dose was too high. No additional furosemide boluses were
administered during the continuous furosemide infusion. The
total administered furosemide dose was 4.97 (2.70–7.02)
mg/kg per 24 hours, 1.63 (0.75–4.31) mg/kg per 24 hours,
and 1.50 (0.09–6.3) mg/kg per 24 hours on the three consec-
utive study days. The total administered furosemide dose over
72 hours was 7.0 (4.97–14.21) mg/kg. The furosemide regi-
men is depicted in Table 1.
The median duration of the continuous furosemide infusion
during ECMO was 70 (19–276) hours, which is in accord-
ance with 75% (37–100%) of the ECMO time. Continuous
furosemide infusion was discontinued 23 (4–120) hours
before decannulation in six patients, and in one patient it was
discontinued 4 hours after decannulation.
Furosemide pharmacokinetics
The apparent volume of distribution was 0.5 (0.2–2.7) l/kg.
The furosemide concentration 10 minutes after the loading
bolus was 1.95 (0.4–4.7) μg/ml, and the concentration in all
of the samples (n = 15) taken during the entire observation
period was 3.1 (0.4–12.9) μg/ml.
Urine output and fluid balance
The overview of the median furosemide dose and urine pro-
duction shows that the urine production first exceeds the tar-
get and is subsequently within the limits (Figure 1). Urine
production from the start of ECMO until the start of furosemide
therapy was 2.2 (0.7–9.6) ml/kg per hour, and increased to
7.9 (0.3–12.0) ml/kg per hour and 6.1 (0.2–9.2) ml/kg per
hour after 8 and 16 hours, respectively, of continuous furosem-
ide infusion. The median urine production over the consecutive
study days was 6.8 (0.8–8.4) ml/kg per hour, 6.0 (4.7–8.9) ml/
kg per hour, and 5.4 (3.4–10.1) ml/kg per hour. An overview
Table 1
Furosemide regimen
Furosemide therapy Before therapy 0–24 hours 24–48 hours 48–72 hours 0–72 hours
Bolus intravenous furosemide
 Patients (n)7
 Mean dose (mg/kg per hour) 1 ± 0.04
Continuous intravenous furosemide
 Patients (n)7 6 5
 Mean dose (mg/kg per hour) 0.17 ± 0.06 0.08 ± 0.04 0.14 ± 0.09
Total intravenous furosemide
 Patients (n)7 6 5
 Median dose (mg/kg per 24 hours) 4.97 (2.70–7.02) 1.24 (0–4.31) 1.60 (0.09–6.4)
 Median dose (mg/kg per 72 hours) 7.00 (4.97–14.3)
Data presented as the mean ± standard deviation or as the median (range).Critical Care    Vol 11 No 5    van der Vorst et al.
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of the median furosemide dose and urine production is
depicted in Table 2.
Over the entire study period the median urine production was
6.7 (4.1–8.8) ml/kg per hour, resulting in a median cumulative
urine production of 369 (168–524) ml/kg.
The target urine production was reached after a median time
of 7 (3–37) hours. Thereafter the median urine production
remained at the target level of 6.0 ml/kg per hour.
Median fluid balances in the first 24 hours, calculated over 8-
hour intervals, were -50.9 ml, +63.1 ml, and +82 ml, respec-
tively. The median 24-hour balance over the three study days
were, respectively, +3 (-267.9 to 624.1) ml, -4.6 (-202.0 to
397.3) ml, and +45 (-430.0 to 283.0) ml.
Cardiovascular effects
The median mean arterial pressure and the heart rate at the
start of ECMO were 48 (37–64) mmHg and 156 (112–170)
beats/minute, and at the start of the furosemide treatment the
respective values were 51 (37–73) mmHg and 146 (131–
170) beats/minute. After 8, 16, 24, 48, and 72 hours of furo-
semide treatment, the median mean arterial pressure and heart
rate were 49 (40–107) mmHg and 161 (136–173) beats/
minute, 52 (39–93) mmHg and 155 (135–175) beats/minute,
52 (46–68) mmHg and 162 (145–181) beats/minute, 51
(50–65) mmHg and 153 (134–185) beats/minute, and 47
(46–48) mmHg and 152 (117–155) beats/minute, respec-
tively. All cardiovascular parameters were within the normal
range for age [13,14].
All patients remained cardiovascularly stable during the admin-
istration of continuous intravenous furosemide, and the ino-
tropic support was gradually decreased during the
observation period. The number of patients requiring inotropic
support was decreased during the study from seven out of
seven patients (100%) to two out of seven patients (29%).
The median vasopressor score at start of ECMO was 20 (5–
130), and that at the start of the continuous furosemide infu-
sion was 15 (0–110). After 8, 16, 24, 48, and 72 hours of con-
tinuous furosemide treatment, the median vasopressor score
was 15 (0–90), 10 (0–90), 20 (0–55), 20 (0–42), and 5 (0–
10), respectively.
Renal function
Median serum creatinine levels at the start of ECMO and at the
start of continuous intravenous furosemide infusion were,
respectively, 35 (19–106) μmol/l and 30 (19–106) μmol/l.
After 24, 48, and 72 hours of continuous intravenous furosem-
ide treatment, the median serum creatinine levels were 41
(16–131) μmol/l, 44 (22–112) μmol/l, and 23 (20–41) μmol/
l, respectively. The median serum BUN level was 2.1 (1.1–3.8)
mmol/l at the start of ECMO, and was 2.2 (1.1–3.8) mmol/l at
the start of continuous intravenous furosemide. After 24, 48,
and 72 hours of furosemide infusion, the median serum BUN
Figure 1
Overview of the median furosemide dose and urine production Overview of the median furosemide dose and urine production.
Table 2
Median furosemide dose and urine production
Furosemide therapy time (hours) Patients (n) Furosemide dose (mg/kg per hour) Urine production (ml/kg per hour)
0 7 0.20 2.2 (0.7–9.6)
8 7 0.20 (0.12–0.24) 7.9 (0.3–12.0)
16 7 0.20 (0.05–0.30) 6.1 (0.2–9.2)
24 7 0.19 (0.04–0.21) 4.7 (2.0–9.4)
32 6 0.10 (0.00–0.16) 6.6 (0.6–9.2)
40 6 0.07 (0.02–0.10) 6.4 (2.4–8.7)
48 6 0.08 (0.03–0.19) 5.8 (4.3–8.0)
56 5 0.10 (0.03–0.30) 6.5 (3.4–10.3)
64 4 0.08 (0.05–0.30) 3.9 (2.3–10.9)
72 4 0.10 (0.05–0.23) 4.8 (3.3–7.9)
Data presented as the median (range).Available online http://ccforum.com/content/11/5/R111
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levels were 3.7 (0.9–8.0) mmol/l, 6.0 (0.9–7.1) mmol/l, and
2.1 (1.5–6.0) mmol/l, respectively. The median serum albumin
levels at the start of ECMO and at the start of furosemide infu-
sion were 24 (19–27) g/l and 26 (23–35) g/l. During continu-
ous intravenous furosemide treatment, the median serum
albumin levels were 28 (25–34) g/l, 28 (25–31) g/l, and 29
(27–29) g/l after 24, 48, and 72 hours, respectively. The renal
function is summarized in Table 3.
Metabolic effects
Metabolic alkalosis, defined as pH > 7.45 and (actual) serum
bicarbonate > 29 mmol/l, was observed in two patients after
48 hours of continuous furosemide infusion. The pH value,
(actual) bicarbonate level, and base excess at the start of
ECMO and during the continuous furosemide treatment are
depicted in Table 3.
Serum electrolytes were within the normal range for age dur-
ing the study (Table 3). Hypochloraemia (92 mmol/l) was
observed in one patient with metabolic alkalosis.
Discussion
Since the observation that continuous intravenous furosemide
might be superior to intermittent administrations in infants after
CPB surgery, the use of continuous furosemide infusion has
increasingly be documented in patients following CPB surgery
[3-6,15]. Based upon the observations in infants after CPB
surgery, the use of continuous intravenous furosemide in
neonates treated with ECMO is increasing.
We recently evaluated furosemide regimens used in neonates
treated with ECMO in our unit and concluded that continuous
intravenous furosemide was frequently used in neonates
(78%) treated with ECMO [7]. The furosemide regimens used
varied widely, in continuous doses and in additional intermit-
tent doses. Although all used regimens achieved adequate
urine output within 24 hours, the use of additional furosemide
bolus injections suggests that the regimens might not be the
optimal for neonates treated with ECMO, and therefore dosing
regimens should be developed [7].
Since ECMO and CPB are 'comparable' procedures, the
developed PK/PD model for infants after CPB surgery might
also be applicable for neonates treated with ECMO [9]. There
are, however, obvious differences between ECMO and CPB:
in the time of exposure to the procedure, and thereby the pres-
ence of the 'circuit' with an ongoing inflammatory reaction, in
the underlying illness and in the age of the patients. We there-
fore conducted a prospective exploratory study in neonates
treated with ECMO to evaluate a suggested furosemide regi-
men developed for infants after CPB surgery. The results sug-
gest that the used regimen was effective and well tolerated in
neonates treated with ECMO.
Continuous intravenous furosemide was started in all patients
at a rate of 0.2 mg/kg per hour and was preceded by a loading
bolus of 1 mg/kg. The furosemide dose was adapted accord-
ing to urine output. The dose was decreased from the first day
to the second day of the study, from 0.17 ± 0.06 mg/kg per
hour to 0.08 ± 0.04 mg/kg per hour. The furosemide doses
used in neonates treated with ECMO (0.17 ± 0.06, 0.08 ±
0.04, and 0.12 ± 0.07 mg/kg per hour) were lower than the
doses used in infants after CPB surgery (0.22 ± 0.06, 0.25 ±
0.10, and 0.22 ± 0.11 mg/kg per hour) over the first day, sec-
ond day, and third day of furosemide therapy, respectively
[16].
Table 3
Renal function and metabolic effects
Start of ECMO 0 hours 24 hours 48 hours 72 hours
Renal function
 Creatinine (μmol/l) 35 (19–106) 29.5 (19–106) 40.5 1(6–131) 44 (22–112) 23 (20–41)
 BUN (mmol/l) 2.05 (1.1–3.8) 2.2 (1.1–3.8) 3.7 (0.9–8) 6 (0.9–7.1) 2.1 (1.5–6)
 Albumin (g/l) 24 (19–27) 26 (23–35) 28 (25–34) 28 (25–31) 29 (27–29)
Acid-base balance
 pH 7.3 (6.97–7.47) 7.4 (7.24–7.47) 7.42 (7.38–7.48) 7.48 (7.43–7.6) 7.47 (7.45–7.67)
 Bicarbonate level (mmol/l) 22.2 (17.4–33.5) 24.2 (17.4–33.5) 29.8 (23.4–35.2) 31.8 (23.8–35.1) 33.9 (26.3–36.5)
 Base excess -4 (-12 to 9) 1 (-9 to 9) 5 (-1 to 10) 7 (1–10) 8 (3–14)
Serum electrolytes
 Sodium (mmol/l) 140 (138–147) 142 (136–147) 136 (132–142) 135 (133–143) 134 (132–141)
 Potassium (mmol/l) 3.3 (3.1–4.1) 3.3 (2.8–5.4) 3.85 (3.2–6.2) 3.6 (3.1–4.1) 3.9 (3.5–5.7)
 Chloride (mmol/l) 106.5 (104–109) 104 (104–104) 102 (100–112) 95 (92–98) 99 (95–107)
Data presented as the median (range). ECMO, extracorporeal membrane oxygenation.Critical Care    Vol 11 No 5    van der Vorst et al.
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The PK/PD model for diuretic therapy with furosemide in
infants after CPB suggested that doses between 0.2 and 0.3
mg/kg per hour, preceded by a loading bolus, would result in
a urine production of 6 ml/kg per hour [9]. Based upon our
observational study, which indicated that relatively low doses
of continuous furosemide were used, we decided to use the
lowest dose suggested by the model. The rational for the load-
ing bolus was based on the simulated urine production profiles
generated with the use of different furosemide regimens and
on the observed effects of the loading bolus in the retrospec-
tive study [7,9].
In the retrospective study, positive effects of the 'loading'
bolus were observed, although not statistically significant, in
the urine output in the first 24 hours and in the time to reach
the desired urine output of 6 ml/kg per hour [7]. Also, no addi-
tional furosemide bolus injections were administered during
the continuous infusion to the patients who received a bolus
prior to the continuous infusion. These observed effects might
suggest that one loading bolus might be sufficient to over-
whelm the effects of the ECMO circuit.
The data from the present study suggest that the starting dose
was too high, as indicated by the urine output exceeding the
target urine output in the first 24 hours. Although a full under-
standing of this phenomenon is hard to reach, it seems logical
to assume that contributing factors might be the ECMO cir-
cuit, the renal function of the patients, and the age of the
patients [17-23]. The patients treated with ECMO were
younger (median 3 days) than the patients after CPB surgery
(median 12 weeks), and therefore by definition had a less
mature renal function, which leads to a decreased renal clear-
ance of furosemide.
The renal function (median creatinine 30 μmol/l) was normal
for age in the ECMO patients, whereas (transient) renal failure
(median creatinine 95 μmol/l) was observed in the majority of
the patients after CPB surgery [12,16]. Therefore it can be
hypothesized that the acute renal failure observed in the
patients after CPB surgery had a major impact on renal clear-
ance, which is most closely related with drug response, since
furosemide is excreted renally and only acts after reaching the
tubular lumen [24-27]. This hypothesis might explain why
higher doses were needed in the patients after CPB surgery.
In addition, phase II reactions are better developed in infants
and, as a result, the percentage of furosemide glucuronide will
be higher [23]. Less unchanged furosemide can therefore be
assumed available to interact with the furosemide receptor in
the infants included in the cardiac surgery study, and higher
doses are consequently needed to reach the same furosemide
excretion rate [25,26]. This assumption might clarify why
higher doses were required in the patients after CPB surgery.
On the other hand, the lower continuous furosemide doses
after the loading bolus used in the ECMO patients might be
explained by the effects of the ECMO circuit [17,18]. The
observed increased volume of distribution in our patients was
in accordance with the values reported in the literature [17].
Wells and colleagues reported that the steady-state volume of
distribution and the elimination half-life of the loop diuretic,
bumetanide, in term neonates treated with ECMO were
increased compared with values in premature and term
neonates without ECMO, while the plasma clearance was sim-
ilar for both groups [17].
The increased volume of distribution is not only due to the
addition of a large exogenous blood volume for priming of the
circuit, but is also caused by the possible absorption of furo-
semide onto the ECMO circuit components [18,28]. Scala
and coworkers performed an in vitro analysis to identify loss of
furosemide in the ECMO circuit and observed a reduction of
63–87% in the serum furosemide concentration over a 4-hour
period. The loss of drug was most pronounced in the first 30
minutes [29]. Since the continuous infusion was started at the
time of the bolus injection, and as only furosemide samples
were taken during the continuous infusion, we could not esti-
mate the furosemide clearance in our patients.
Mehta and colleagues recently published research on the
potential sequestration of drugs to the ECMO circuit. In vivo
experiments showed that there was a significant drug loss in
crystalloid-primed circuits as well as in blood-primed circuits.
For instance, the loss of analgetics ranged from 17% for mor-
phine to 87–100% for fentanyl depending on the type of cir-
cuit [30]. In addition, our own group described a decreased
clearance of morphine during the first 10 days of ECMO in
neonates and infants treated with venoarterial ECMO com-
pared with patients after noncardiac major surgery [31,32].
The furosemide loading bolus especially seems to compen-
sate for the increased volume of distribution. Since the effects
of furosemide are dependent on renal function, the apparent
need for lower continuous furosemide dose might be
explained by the absence of impaired renal function, and con-
sequently the increased renal clearance, in the patients on
ECMO compared with the patients post CPB surgery [24].
We previously noticed that additional loop diuretics were
needed in approximately 40% of the patients on ECMO ther-
apy during the continuous furosemide infusion [7]. In the
present study no additional loop diuretics were needed, dem-
onstrating that furosemide monotherapy is highly effective,
which is a considerable advantage.
The total administered furosemide dose in the current study
was substantial higher on the first day (4.97 mg/kg per 24
hours) than the dose used in our retrospective study (1.92 mg/
kg per 24 hours). The respective doses were slightly lower on
the second day and third day (1.63 mg/kg per 24 hours and
1.50 mg/kg per 24 hours in the present study compared withAvailable online http://ccforum.com/content/11/5/R111
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1.92 mg/kg per 24 hours and 2.0 mg/kg per 24 hours in the
retrospective study). The cumulative furosemide doses over
the three study days, however, were comparable between the
two studies. The cumulative furosemide dose in the current
study showed less variation in dose [7]. Importantly serum
furosemide levels remained far below the commonly accepted
safety level for ototoxicity (50 μg/ml) [33].
To obtain an acceptable fluid balance with a maintenance fluid
of 120–140 ml/kg per 24 hours, the target urine production is
set at 6 ml/kg per hour in our unit. In all patients studied, the
target urine production of 6 ml/kg per hour was obtained a
median 7 hours after the start of the continuous infusion. This
is considerable faster than in our retrospective study in which
the target urine production was reached in median 24 hours.
The rapid attainment of the target urine may be explained by
the initial higher infusion rate and the loading bolus.
The observed variability in urine output was small (4.1–8.8 ml/
kg per hour) throughout the entire observation period –
although it was striking that in one patient, despite administra-
tion of a high dose of furosemide, the urine output remained
low, if not negligible, for a period of approximately 33 hours.
We could not identify an obvious cause for this. In our retro-
spective study in which the patients received additional inter-
mittent furosemide bolus injections, the variability in urine
output was 0.7–16.1 ml/kg per hour during the study period.
This is in accordance with studies in infants after CPB surgery,
where less variance in urine output was observed with contin-
uous administration compared with intermittent furosemide
administration [3-5]. This suggests that strict protocols for diu-
retic therapies reduce variability in patients' response. It is
probable that a tailored PK/PD model for furosemide therapy
in neonates treated with ECMO may further optimize diuretic
therapy for these critically ill neonates.
The obtained fluid balances were approximately zero for all
three study days, although with substantial variability. The
forced diuresis was well tolerated, as shown by the stable
haemodynamic parameters and by the reduction of the vaso-
pressor score.
Hypochloraemic metabolic alkalosis is a well-known side
effect of furosemide therapy. A tendency for metabolic alkalo-
sis was observed in two patients after approximately 48 hours
of furosemide therapy. Since hypochloraemia was present in
one patient, furosemide therapy was most probably the cause
of the metabolic alkalosis. We have no explanation, however,
for the metabolic alkalosis in the other patient, after contrac-
tion alkalosis and prerenal failure were excluded, and no
increased use of inotropic drugs was present. This aspect
should be recognized in the ongoing development and testing
of a PK/PD model including more patients.
Conclusion
The evaluated furosemide regimen of 0.2 mg/kg per hour pre-
ceded by a loading of 1 mg/kg is an effective means to obtain
rapid and sufficient diuresis without cardiovascular instability
in neonates treated with ECMO with a relatively low interpa-
tient variability in urine production. The present exploratory
study, however, suggests that for neonates on ECMO the pro-
posed furosemide regimen as used in infants after CPB is
using furosemide doses for the continuous infusion that are
too high. A PK/PD model should therefore be developed for
neonates on ECMO, identifying factors such as the circuit age,
renal function and albumin that influence drug disposition dur-
ing ECMO.
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